CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma

CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma

Abstract Background Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we inv...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Junya Yamaguchi, Fumiharu Ohka, Chalise Lushun, Kazuya Motomura, Kosuke Aoki, Kazuhito Takeuchi, Yuichi Nagata, Satoshi Ito, Nobuhiko Mizutani, Masasuke Ohno, Noriyuki Suzaki, Syuntaro Takasu, Yukio Seki, Takahisa Kano, Kenichi Wakabayashi, Hirofumi Oyama, Shingo Kurahashi, Kuniaki Tanahashi, Masaki Hirano, Hiroyuki Shimizu, Yotaro Kitano, Sachi Maeda, Shintaro Yamazaki, Toshihiko Wakabayashi, Yutaka Kondo, Atsushi Natsume, Ryuta Saito
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Wiley 2023-03-01
Sraith:Cancer Medicine
Ábhair:
CD79B
MYD88
primary central nervous system lymphoma
rapid molecular diagnosis
R‐MPV
Rochtain ar líne:https://doi.org/10.1002/cam4.5512

Ar líne

https://doi.org/10.1002/cam4.5512

Míreanna comhchosúla